Supplementary Figure S1 . CDI (% of transcripts) of OverT and UnderT in all chromosomes of each selected CRC group.
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Supplementary Figure S2 . CDI of Over-PositiveT in selected chromosome of gain CRC groups at different FC3 or FC4 thresholds. CDI in selected chromosome for each group are calculated at progressively increasing FC3-or FC4-threshold (higher than the value indicated in abscissa) while keeping constant the FC2 threshold (>1.3). Horizontal dashed line indicates the CDI value of OverT (FC2>1.3; no threshold for FC3 and FC4).
6 Supplementary Figure S3 . Varying FC2 thresholds for definition of transcript classes. CDI of Over-UpT and Over-DownT in selected chromosome of gain CRC groups at different FC2 thresholds. CDI in selected chromosome for each group are calculated at progressively increasing FC2-threshold (higher than the value indicated in abscissa) while keeping constant the FC3 threshold for UpT (>1.5) or DownT (<-1.5). Table S1 . Clinicopathological (age, sex, anatomical site, stage) and molecular (microsatellite instability status, activating KRAS mutations, Consensus Molecular Subtypes according to Guinney et al., 2015) Supplementary Table S2 . Frequency of somatic broad genomic aberrations in the "Chr7-, 8q-, 9-, 13-, 20-gain" groups, in the "Chr18-,8p-loss" groups, and in "Chr6-, 22-CNLOH" groups. 0  17  28  10  0  0  3  10  0  0  0  10  38  3  3  66  14  0  7  14  10  3   p   21  0  7  7  0  0  0  59  3  3  0  10  0  0  0  0  48  0  3  17  0  0  0 
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